Literature DB >> 7503230

Angiotensin IV receptors and signaling in opossum kidney cells.

N Dulin1, Z T Madhun, C H Chang, L Berti-Mattera, D Dickens, J G Douglas.   

Abstract

The pharmacological properties and signaling of angiotensin IV (ANG IV) receptors were studied in opossum kidney cell line OK7A. Saturation binding experiments with 125I-labeled ANG IV demonstrated the presence of high-affinity ANG IV binding sites in OK7A cell membranes with a dissociation constant (Kd) of 0.40 +/- 0.08 nM and a maximal amount of binding sites (Bmax) of 180 +/- 50 fmol/mg protein. In competition experiments, unlabeled ANG IV inhibited 125I-ANG IV binding biphasically: 20% of binding sites had high affinity [inhibition constant (Ki) = 0.44 +/- 0.04 nM] and 80% had low affinity (Ki = 130 +/- 10 nM). ANG III displaced 125I-ANG IV from binding sites with low affinity (Ki = 205 +/- 10 nM), and ANG II did not compete with 125I-ANG IV at concentrations up to 10 microM. The binding of ANG IV to OK7A cell membranes was significantly enhanced in the presence of 5 mM EDTA and completely blocked by 5 mM dithiothreitol. Guanosine 5'-O-(3-thiotriphosphate) inhibited the binding of 125I-ANG IV, indicating the G protein coupling of ANG IV receptors in OK7A cells. In signaling studies, ANG IV induced transient increase in intracellular calcium concentration ([Ca2+]i) from 49 +/- 3 to 280 +/- 45 nM. ANG IV failed to influence phosphoinositol metabolism, indicating that Ca2+ mobilization is not linked to ANG IV signaling. Ethylene glycol-bis(beta-aminoethylether)-N,N,N',N'-tetraacetic acid completely abolished ANG IV-induced increase in [Ca2+]i, consistent with Ca2+ influx. The voltage-sensitive Ca2+ channel blocking agents verapamil and nifedipine attenuated the effect of ANG IV on [Ca2+]i to 133 +/- 33 and 174 +/- 32 nM, respectively. These data suggest that ANG IV induces Ca2+ influx in OK7A cells, at least partially, through the voltage-sensitive Ca2+ channels.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7503230     DOI: 10.1152/ajprenal.1995.269.5.F644

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

Review 1.  The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.

Authors:  John W Wright; Joseph W Harding
Journal:  Pflugers Arch       Date:  2012-04-26       Impact factor: 3.657

2.  Angiotensin IV upregulates the activity of protein phosphatase 1α in Neura-2A cells.

Authors:  Dan Wang; Peng Xue; Xiu Lan Chen; Zhen Sheng Xie; Fu Quan Yang; Li Zheng; Tao Xu
Journal:  Protein Cell       Date:  2013-06-06       Impact factor: 14.870

Review 3.  New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II.

Authors:  Jia L Zhuo; Xiao C Li
Journal:  Peptides       Date:  2011-06-14       Impact factor: 3.750

4.  AT1 receptor-activated signaling mediates angiotensin IV-induced renal cortical vasoconstriction in rats.

Authors:  Xiao C Li; Duncan J Campbell; Mitsuru Ohishi; Shao Yuan; Jia L Zhuo
Journal:  Am J Physiol Renal Physiol       Date:  2005-12-27

Review 5.  Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review.

Authors:  Bart Stragier; Dimitri De Bundel; Sophie Sarre; Ilse Smolders; Georges Vauquelin; Alain Dupont; Yvette Michotte; Patrick Vanderheyden
Journal:  Heart Fail Rev       Date:  2007-11-08       Impact factor: 4.214

Review 6.  Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets.

Authors:  John W Wright; Brent J Yamamoto; Joseph W Harding
Journal:  Prog Neurobiol       Date:  2007-11-19       Impact factor: 11.685

7.  RGS3 inhibits G protein-mediated signaling via translocation to the membrane and binding to Galpha11.

Authors:  N O Dulin; A Sorokin; E Reed; S Elliott; J H Kehrl; M J Dunn
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

Review 8.  Aminopeptidase N in arterial hypertension.

Authors:  Robert S Danziger
Journal:  Heart Fail Rev       Date:  2007-11-16       Impact factor: 4.214

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.